Wildcat Capital Management buys $18,254,631 stake in Sorrento Therapeutics Inc (SRNE)

Sorrento Therapeutics Inc (SRNE) : Wildcat Capital Management scooped up 176,257 additional shares in Sorrento Therapeutics Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 11, 2016. The investment management firm now holds a total of 2,799,790 shares of Sorrento Therapeutics Inc which is valued at $18,254,631.Sorrento Therapeutics Inc makes up approximately 2.64% of Wildcat Capital Management’s portfolio.

Other Hedge Funds, Including , Baird Financial Group reduced its stake in SRNE by selling 50,171 shares or 19.23% in the most recent quarter. The Hedge Fund company now holds 210,777 shares of SRNE which is valued at $1,374,266. Sorrento Therapeutics Inc makes up approx 0.01% of Baird Financial Group’s portfolio.Gagnon Securities boosted its stake in SRNE in the latest quarter, The investment management firm added 60 additional shares and now holds a total of 11,191 shares of Sorrento Therapeutics Inc which is valued at $72,965. Sorrento Therapeutics Inc makes up approx 0.03% of Gagnon Securities’s portfolio.Cutler Group Lp reduced its stake in SRNE by selling 1,400 shares or 59.5% in the most recent quarter. The Hedge Fund company now holds 953 shares of SRNE which is valued at $5,975.

Sorrento Therapeutics Inc opened for trading at $7 and hit $7.22 on the upside on Tuesday, eventually ending the session at $6.96, with a gain of 0.14% or 0.01 points. The heightened volatility saw the trading volume jump to 3,88,771 shares. Company has a market cap of $401 M.

Sorrento Therapeutics Inc. is a biopharmaceutical company. The Company is engaged in the discovery acquisition development and commercialization of drug therapeutics for addressing unmet medical needs in the United States Europe as well as international markets. Its primary therapeutic focus is oncology including the treatment of chronic cancer pain but it is also developing therapeutic products for other indications including immunology and infectious diseases. Its products in the pipeline include Cynviloq and resiniferatoxin (RTX) a non-opiate ultra-potent and selective agonist of the transient receptor potential cation channel subfamily V member 1 (TRPV-1) receptor. Its pipeline also includes preclinical human therapeutic monoclonal antibodies (mAbs) antibody drug conjugates (ADCs) bispecific antibodies (BsAbs) as well as Chimeric Antigen Receptor Tumor-attacking Neukoplast (CAR.TNK) for adoptive cellular immunotherapies (ACI).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *